These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32558473)

  • 21. [Prostate cancer screening: Reasons of controversy].
    Delporte G; Villers A; Penel N
    Bull Cancer; 2018 Dec; 105(12):1111-1118. PubMed ID: 30458966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate specific antigen for detecting early prostate cancer.
    Ilic D; Green S
    BMJ; 2009 Sep; 339():b3572. PubMed ID: 19778970
    [No Abstract]   [Full Text] [Related]  

  • 23. The Melbourne Consensus Statement on the early detection of prostate cancer.
    Murphy DG; Ahlering T; Catalona WJ; Crowe H; Crowe J; Clarke N; Cooperberg M; Gillatt D; Gleave M; Loeb S; Roobol M; Sartor O; Pickles T; Wootten A; Walsh PC; Costello AJ
    BJU Int; 2014 Feb; 113(2):186-8. PubMed ID: 24206066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study Finds Overall Prostate Cancer Mortality Decreases with PSA Screening.
    Zolot J
    Am J Nurs; 2017 Dec; 117(12):16. PubMed ID: 29189229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC).
    Bokhorst LP; Zappa M; Carlsson SV; Kwiatkowski M; Denis L; Paez A; Hugosson J; Moss S; Auvinen A; Roobol MJ
    BJU Int; 2016 Nov; 118(5):677-680. PubMed ID: 27104278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer screening--the evidence, the recommendations, and the clinical implications.
    Chou R; LeFevre ML
    JAMA; 2011 Dec; 306(24):2721-2. PubMed ID: 22203543
    [No Abstract]   [Full Text] [Related]  

  • 27. A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality.
    Zappa M; Puliti D; Hugosson J; Schröder FH; van Leeuwen PJ; Kranse R; Auvinen A; Carlsson S; Kwiatkowski M; Nelen V; Paez Borda A; Roobol MJ; Villers A
    Eur Urol; 2014 Sep; 66(3):401-3. PubMed ID: 24412230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspective: Enforce the clinical guidelines.
    Roobol M
    Nature; 2015 Dec; 528(7582):S123. PubMed ID: 26672782
    [No Abstract]   [Full Text] [Related]  

  • 29. Screening for prostate cancer remains controversial.
    Neal DE; Donovan JL; Martin RM; Hamdy FC
    Lancet; 2009 Oct; 374(9700):1482-3. PubMed ID: 19664817
    [No Abstract]   [Full Text] [Related]  

  • 30. Prostate cancer screening: and yet it moves!
    Kwiatkowski M; Randazzo M; Kluth L; Manka L; Huber A; Recker F
    Asian J Androl; 2015; 17(3):437-8. PubMed ID: 25532573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
    Hayes JH; Barry MJ
    JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
    Ito K
    Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.
    Gulati R; Mariotto AB; Chen S; Gore JL; Etzioni R
    J Clin Epidemiol; 2011 Dec; 64(12):1412-7. PubMed ID: 22032753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-specific antigen: a new(ish) study.
    Harv Mens Health Watch; 2010 Nov; 15(4):6-8. PubMed ID: 21166115
    [No Abstract]   [Full Text] [Related]  

  • 35. Prostate cancer: PSA velocity in prostate cancer screening--the debate continues.
    Borofsky MS; Makarov DV
    Nat Rev Urol; 2011 Jul; 8(8):413-4. PubMed ID: 21750502
    [No Abstract]   [Full Text] [Related]  

  • 36. PSA screening: the USPSTF got it right.
    Lefevre M
    J Fam Pract; 2013 Nov; 62(11):617, 619. PubMed ID: 24288702
    [No Abstract]   [Full Text] [Related]  

  • 37. Prostate-specific antigen testing: good or bad?
    Albertsen PC
    Oncologist; 2015 Mar; 20(3):233-5. PubMed ID: 25673105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer screening can save lives but it is too early for a national programme, study finds.
    Sayburn A
    BMJ; 2014 Aug; 349():g5055. PubMed ID: 25102993
    [No Abstract]   [Full Text] [Related]  

  • 39. First, do no harm.
    Pimlott N
    Can Fam Physician; 2012 Sep; 58(9):915. PubMed ID: 22972717
    [No Abstract]   [Full Text] [Related]  

  • 40. Early versus delayed intervention for prostate cancer: the case for early intervention.
    Loeb S; Catalona WJ
    Nat Clin Pract Urol; 2007 Jul; 4(7):348-9. PubMed ID: 17563779
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.